JP2012533288A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012533288A5 JP2012533288A5 JP2012520048A JP2012520048A JP2012533288A5 JP 2012533288 A5 JP2012533288 A5 JP 2012533288A5 JP 2012520048 A JP2012520048 A JP 2012520048A JP 2012520048 A JP2012520048 A JP 2012520048A JP 2012533288 A5 JP2012533288 A5 JP 2012533288A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- disease
- syndrome
- thrombosis
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001184 polypeptide Polymers 0.000 claims 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 208000007536 Thrombosis Diseases 0.000 claims 7
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims 6
- 206010040047 Sepsis Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 201000001320 Atherosclerosis Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 210000000056 organ Anatomy 0.000 claims 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 208000037803 restenosis Diseases 0.000 claims 4
- 201000003068 rheumatic fever Diseases 0.000 claims 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 3
- 206010053567 Coagulopathies Diseases 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 206010063837 Reperfusion injury Diseases 0.000 claims 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 3
- 208000001435 Thromboembolism Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 3
- 230000015572 biosynthetic process Effects 0.000 claims 3
- 208000015294 blood coagulation disease Diseases 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 230000015271 coagulation Effects 0.000 claims 3
- 238000005345 coagulation Methods 0.000 claims 3
- 210000004351 coronary vessel Anatomy 0.000 claims 3
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 206010008088 Cerebral artery embolism Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 102000009123 Fibrin Human genes 0.000 claims 2
- 108010073385 Fibrin Proteins 0.000 claims 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 108010087870 Mannose-Binding Lectin Proteins 0.000 claims 2
- 102100026553 Mannose-binding protein C Human genes 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- 208000009525 Myocarditis Diseases 0.000 claims 2
- 206010028851 Necrosis Diseases 0.000 claims 2
- 206010050902 Postoperative thrombosis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 2
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 238000002399 angioplasty Methods 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims 2
- 230000008021 deposition Effects 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 206010014665 endocarditis Diseases 0.000 claims 2
- 229950003499 fibrin Drugs 0.000 claims 2
- 108090000062 ficolin Proteins 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 201000010849 intracranial embolism Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 201000004792 malaria Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 230000017074 necrotic cell death Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- 208000008494 pericarditis Diseases 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 230000002537 thrombolytic effect Effects 0.000 claims 2
- 201000005060 thrombophlebitis Diseases 0.000 claims 2
- 230000001732 thrombotic effect Effects 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010000228 Abortion infected Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000004881 Amebiasis Diseases 0.000 claims 1
- 206010001980 Amoebiasis Diseases 0.000 claims 1
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003011 Appendicitis Diseases 0.000 claims 1
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 208000031729 Bacteremia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 241000222122 Candida albicans Species 0.000 claims 1
- 206010007134 Candida infections Diseases 0.000 claims 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009895 Colitis ischaemic Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 102100024206 Collectin-10 Human genes 0.000 claims 1
- 101710194645 Collectin-10 Proteins 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 206010016228 Fasciitis Diseases 0.000 claims 1
- 102100024508 Ficolin-1 Human genes 0.000 claims 1
- 101710155257 Ficolin-1 Proteins 0.000 claims 1
- 102100024521 Ficolin-2 Human genes 0.000 claims 1
- 101710155249 Ficolin-2 Proteins 0.000 claims 1
- 102100024520 Ficolin-3 Human genes 0.000 claims 1
- 101710155250 Ficolin-3 Proteins 0.000 claims 1
- 201000006353 Filariasis Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010020843 Hyperthermia Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 208000024781 Immune Complex disease Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000034486 Multi-organ failure Diseases 0.000 claims 1
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 claims 1
- 206010037128 Pseudomembranous colitis Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 claims 1
- 102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 208000002359 Septic Abortion Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- 208000000260 Warts Diseases 0.000 claims 1
- 208000027207 Whipple disease Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 201000005008 bacterial sepsis Diseases 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000003984 candidiasis Diseases 0.000 claims 1
- 208000003167 cholangitis Diseases 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 230000009852 coagulant defect Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000007123 defense Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 208000007784 diverticulitis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 208000003401 eosinophilic granuloma Diseases 0.000 claims 1
- 210000000918 epididymis Anatomy 0.000 claims 1
- 201000010063 epididymitis Diseases 0.000 claims 1
- 208000001606 epiglottitis Diseases 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 208000024326 hypersensitivity reaction type III disease Diseases 0.000 claims 1
- 230000036031 hyperthermia Effects 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 201000008222 ischemic colitis Diseases 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 239000003580 lung surfactant Substances 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000008423 pleurisy Diseases 0.000 claims 1
- 206010035653 pneumoconiosis Diseases 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 210000004994 reproductive system Anatomy 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 208000013223 septicemia Diseases 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 201000010153 skin papilloma Diseases 0.000 claims 1
- 239000003998 snake venom Substances 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 208000025883 type III hypersensitivity disease Diseases 0.000 claims 1
- 208000000143 urethritis Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09165770 | 2009-07-17 | ||
| EP09165770.0 | 2009-07-17 | ||
| EP09171941.9 | 2009-10-01 | ||
| EP09171941 | 2009-10-01 | ||
| US31104910P | 2010-03-05 | 2010-03-05 | |
| US61/311,049 | 2010-03-05 | ||
| PCT/EP2010/060279 WO2011006982A2 (en) | 2009-07-17 | 2010-07-16 | Inhibitors of complement activation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015203735A Division JP6290845B2 (ja) | 2009-07-17 | 2015-10-15 | 補体活性化の阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012533288A JP2012533288A (ja) | 2012-12-27 |
| JP2012533288A5 true JP2012533288A5 (enExample) | 2013-07-25 |
Family
ID=43449884
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520048A Withdrawn JP2012533288A (ja) | 2009-07-17 | 2010-07-16 | 補体活性化の阻害剤 |
| JP2015203735A Active JP6290845B2 (ja) | 2009-07-17 | 2015-10-15 | 補体活性化の阻害剤 |
| JP2018018979A Active JP6820286B2 (ja) | 2009-07-17 | 2018-02-06 | 補体活性化の阻害剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015203735A Active JP6290845B2 (ja) | 2009-07-17 | 2015-10-15 | 補体活性化の阻害剤 |
| JP2018018979A Active JP6820286B2 (ja) | 2009-07-17 | 2018-02-06 | 補体活性化の阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20120282285A1 (enExample) |
| EP (2) | EP3395828A1 (enExample) |
| JP (3) | JP2012533288A (enExample) |
| KR (2) | KR102184713B1 (enExample) |
| CN (2) | CN107513103A (enExample) |
| AU (1) | AU2010272483B2 (enExample) |
| BR (1) | BR112012001070B1 (enExample) |
| CA (1) | CA2767755C (enExample) |
| WO (1) | WO2011006982A2 (enExample) |
| ZA (1) | ZA201200953B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US9644035B2 (en) * | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| KR20220044616A (ko) | 2011-04-08 | 2022-04-08 | 유니버시티 오브 레스터 | Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법 |
| US20140120105A1 (en) * | 2011-06-28 | 2014-05-01 | Kobenhavns Universitet | Therapeutic targeting of ficolin-3 |
| CA3087933A1 (en) * | 2012-04-06 | 2013-12-05 | Omeros Corporation | Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria |
| CN118924900A (zh) * | 2012-06-18 | 2024-11-12 | 奥默罗斯公司 | 抑制masp-1和/或masp-2和/或masp-3的组合物和方法 |
| ES2878749T3 (es) | 2013-02-20 | 2021-11-19 | Innate Pharma | Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico |
| WO2015058143A1 (en) | 2013-10-17 | 2015-04-23 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
| JP6634566B2 (ja) * | 2015-03-06 | 2020-01-22 | 株式会社森永生科学研究所 | コントロールスライド及びコントロール実験の方法 |
| JOP20170154B1 (ar) | 2016-08-01 | 2023-03-28 | Omeros Corp | تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة |
| JP6143209B1 (ja) * | 2016-10-31 | 2017-06-07 | 国立大学法人大阪大学 | 自己免疫疾患用または難治性血管炎用の治療剤、および、これらの疾患の診断のためのデータの取得方法 |
| KR102094802B1 (ko) * | 2017-10-24 | 2020-03-31 | 고려대학교 산학협력단 | 소변 대사체 분석을 이용한 베체트병의 진단방법 |
| CN109829885B (zh) * | 2018-12-24 | 2022-07-22 | 广州柏视医疗科技有限公司 | 一种基于深度语义分割网络的自动识别鼻咽癌原发肿瘤方法 |
| KR102316999B1 (ko) * | 2019-03-20 | 2021-10-26 | (주)레티마크 | 실명 유발 주요 안질환 진단용 혈액 마커 및 이를 이용한 진단 방법 |
| SG11202111587VA (en) * | 2019-05-07 | 2021-11-29 | Bayer Ag | Masp inhibitory compounds and uses thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4203570A (en) | 1978-08-23 | 1980-05-20 | The Western States Machine Company | Power-operated loading gate for centrifugal machines incorporating an auxiliary drive device |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4546082A (en) | 1982-06-17 | 1985-10-08 | Regents Of The Univ. Of California | E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins |
| US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| WO1984004330A1 (en) | 1983-04-22 | 1984-11-08 | Amgen | Secretion of exogenous polypeptides from yeast |
| NZ207926A (en) | 1983-04-25 | 1988-04-29 | Genentech Inc | Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast |
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
| US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
| DK58285D0 (da) | 1984-05-30 | 1985-02-08 | Novo Industri As | Peptider samt fremstilling og anvendelse deraf |
| US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| US4885249A (en) | 1984-12-05 | 1989-12-05 | Allelix, Inc. | Aspergillus niger transformation system |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| AU607398B2 (en) | 1985-08-29 | 1991-03-07 | Genencor Inc. | Heterologous polypeptides expressed in filamentous fungi, processes for making same, and vectors for making same |
| US4754051A (en) * | 1985-09-30 | 1988-06-28 | Dainippon Ink And Chemicals, Inc. | Optically active tolan derivative |
| US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
| HU206897B (en) | 1985-10-25 | 1993-01-28 | Zymogenetics Inc | Process for utilizing bar-1 gen for selecting strange proteins |
| US4935349A (en) * | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
| DK122686D0 (da) | 1986-03-17 | 1986-03-17 | Novo Industri As | Fremstilling af proteiner |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| GB8615942D0 (en) | 1986-06-30 | 1986-08-06 | Animal & Food Research Council | Peptide production |
| NZ221259A (en) | 1986-07-31 | 1990-05-28 | Calgene Inc | Seed specific transcriptional regulation |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| US4873316A (en) * | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| DE3856247T2 (de) | 1987-07-24 | 1999-04-29 | Chiron Corp., Emeryville, Calif. | Züchtung von insektenzellen mit airlift-reaktoren |
| US5024947A (en) | 1987-07-24 | 1991-06-18 | Cetus Corporation | Serum free media for the growth on insect cells and expression of products thereby |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| JP2703598B2 (ja) | 1987-09-04 | 1998-01-26 | ノボ―ノルディスク アクティーゼルスカブ | アスペルギルス菌中でのタンパク質生産物の生産方法およびアスペルギルス菌中で使用するためのプロモーター |
| DK463887D0 (da) | 1987-09-07 | 1987-09-07 | Novo Industri As | Gaerleader |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| GB8826446D0 (en) | 1988-11-11 | 1988-12-14 | Agricultural & Food Res | Peptide production |
| WO1990005783A1 (en) | 1988-11-18 | 1990-05-31 | Cetus Corporation | Insect signal peptide mediated secretion of recombinant proteins |
| GB8910962D0 (en) | 1989-05-12 | 1989-06-28 | Natural Environment Res | Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells |
| US5077214A (en) | 1989-07-07 | 1991-12-31 | The Texas A&M University System | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells |
| US5162222A (en) | 1989-07-07 | 1992-11-10 | Guarino Linda A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses |
| US5023328A (en) | 1989-08-04 | 1991-06-11 | The Texas A&M University System | Lepidopteran AKH signal sequence |
| US5155037A (en) | 1989-08-04 | 1992-10-13 | The Texas A&M University System | Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems |
| US5073964A (en) | 1989-08-04 | 1991-12-17 | Aware, Inc. | Signal processing device and method |
| DK300090D0 (da) | 1990-12-19 | 1990-12-19 | Novo Nordisk As | Fremgangsmaade til fremstilling af leadersekvenser |
| JPH06507307A (ja) | 1991-01-11 | 1994-08-25 | アメリカン・レツド・クロス | トランスジェニック動物の乳腺組織における活性ヒトプロテインｃの発現 |
| US6969601B2 (en) * | 1997-04-03 | 2005-11-29 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| AU785149B2 (en) | 1999-12-02 | 2006-10-05 | Jens Christian Jensenius | MASP-3, a complement-fixing enzyme, and uses for it |
| WO2002006460A2 (en) | 2000-07-13 | 2002-01-24 | Jens Christian Jensenius | Masp-2, a complement-fixing enzyme, and uses for it |
| JP2005526084A (ja) * | 2002-03-15 | 2005-09-02 | ナットイムネ・アクティーゼルスカブ | マンノース結合レクチンを含む医薬組成物 |
| US7666627B2 (en) | 2002-08-08 | 2010-02-23 | Targetex Kft. | Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof |
| CN1694961A (zh) * | 2002-09-10 | 2005-11-09 | 内蒂穆恩公司 | 胶原凝集素－补体激活蛋白嵌合体 |
| PL2465534T3 (pl) * | 2004-06-10 | 2017-08-31 | Omeros Corporation | Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2 |
| WO2007047995A2 (en) * | 2005-10-21 | 2007-04-26 | Catalyst Biosciences, Inc. | Modified proteases that inhibit complement activation |
| EP2403870A1 (en) * | 2009-03-03 | 2012-01-11 | Metamorefix Ltd. | Peptides derived from ficolin as surfactants |
-
2010
- 2010-07-16 CN CN201710287596.1A patent/CN107513103A/zh active Pending
- 2010-07-16 CN CN2010800413216A patent/CN102712687A/zh active Pending
- 2010-07-16 CA CA2767755A patent/CA2767755C/en active Active
- 2010-07-16 EP EP18171378.5A patent/EP3395828A1/en active Pending
- 2010-07-16 KR KR1020187005648A patent/KR102184713B1/ko active Active
- 2010-07-16 BR BR112012001070-0A patent/BR112012001070B1/pt active IP Right Grant
- 2010-07-16 WO PCT/EP2010/060279 patent/WO2011006982A2/en not_active Ceased
- 2010-07-16 US US13/383,676 patent/US20120282285A1/en not_active Abandoned
- 2010-07-16 EP EP10737833.3A patent/EP2454281B1/en active Active
- 2010-07-16 AU AU2010272483A patent/AU2010272483B2/en active Active
- 2010-07-16 JP JP2012520048A patent/JP2012533288A/ja not_active Withdrawn
- 2010-07-16 KR KR1020127004301A patent/KR101870378B1/ko active Active
-
2012
- 2012-02-08 ZA ZA2012/00953A patent/ZA201200953B/en unknown
-
2015
- 2015-10-15 JP JP2015203735A patent/JP6290845B2/ja active Active
-
2017
- 2017-05-31 US US15/609,660 patent/US11203622B2/en active Active
-
2018
- 2018-02-06 JP JP2018018979A patent/JP6820286B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012533288A5 (enExample) | ||
| JP2013520979A5 (enExample) | ||
| JP6181145B2 (ja) | 改善された特異性を有する新規免疫グロブリン結合タンパク質 | |
| JP2025066728A (ja) | アネキシンｖの製造プロセス | |
| Dreier et al. | Rapid selection of high-affinity binders using ribosome display | |
| Gao et al. | Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect | |
| JP2014518883A5 (enExample) | ||
| RU2714156C2 (ru) | С5-связующие полипептиды | |
| US11598769B2 (en) | Oligomerized protein-polymer conjugates | |
| JP6657177B2 (ja) | 改良型β−フルクトフラノシダーゼ | |
| JP5550797B2 (ja) | ヒト心筋由来トロポニンｉに特異的にかつ速やかに結合できる変異体タンパク質 | |
| JP5528643B2 (ja) | ヒト心筋由来トロポニンｉに特異的にかつ速やかに結合できる組み換えタンパク質 | |
| JP2012514465A5 (enExample) | ||
| Grimm et al. | Monitored whole gene in vitro evolution of an anti-hRaf-1 affibody molecule towards increased binding affinity | |
| RU2011133060A (ru) | Новые полипептиды и их применение | |
| Jian et al. | Multiple mechanisms are involved in repression of filamentous phage SW1 transcription by the DNA-binding protein FpsR | |
| CN103804496B (zh) | 一种特异性识别并结合Aβ42寡聚体的单链抗体及单链抗体基因 | |
| JP2013172663A (ja) | ヒト心筋由来トロポニンＩとの高い親和性を有するｓｃＦｖ抗体フラグメント | |
| CN105237637B (zh) | 抗人神经纤毛蛋白1的单域抗体及其制备方法 | |
| KR20160110903A (ko) | 팔라듐 이온 특이적 dna 앱타머 및 이의 선별 방법 | |
| Ling et al. | Interaction Affinity Determination of SUMO E1 Heterodimer Aos1/Uba2 and intermediates of activation cascade by Quantitative FRET Analysis | |
| KR101679140B1 (ko) | 팔라듐 이온 특이적 dna 앱타머 및 이의 선별 방법 | |
| CN119708236A (zh) | 一种结合cdh17的重组c-型单域纳米抗体及其应用 | |
| JP2019535249A (ja) | ＴＮＦ−α結合アプタマー及びその治療的用途 | |
| CN109157654B (zh) | Tmx1的用途 |